Concepedia

Andrzej Pluta

AP

Statistics

Publications

15

Citations

2.2K

H-Index

14

Active since

2004

Affiliations

Medical University of Lublin(Current)

University Hospital Hradec Králové

University of Debrecen

AstraZeneca (United States)

Saint John Regional Hospital

Andrzej Pluta is an author at Medical University of Lublin specializing in medicine, hematologic malignancy therapy, and pharmacotherapy.

Publications per year

2004–2022

15

Publications

15

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

, , +12

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

, , +11

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, Andrzej Pluta, Daniel Lysák et al. · Journal of Clinical Oncology · 2020 · 362 citations · Full text

, , +14

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

, , +15

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Hervé Avet‐Loiseau, Nizar J. Bahlis, Wee Joo Chng et al. · Blood · 2017 · 113 citations · Full text

, , +10

1–5 of 15